Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd.’s subsidiary Glenmark Specialty S.A., entered a marketing and distribution agreement with BeiGene, a global oncology company. This partnership will see Glenmark handle the local development, registration, and distribution of BeiGene’s oncology medicines, Tislelizumab and Zanubrutinib, in India. Tislelizumab, an anti-PD-1 monoclonal antibody, is approved for advanced esophageal squamous cell carcinoma, among other cancers, while Zanubrutinib, a BTK inhibitor, is used for certain hematological malignancies.

Glenmark Pharmaceuticals Ltd. has received final approval from the United States Food & Drug Administration (USFDA) for Acetaminophen and Ibuprofen tablets, 250 mg/125 mg (OTC).